AQEMIA

Executive Summary

AQEMIA is a Paris-based biotechnology company founded in 2019 that is reinventing drug discovery by combining generative AI with proprietary, fast physics-based algorithms. Its platform, QEMI, predicts drug-target interactions from first principles, eliminating the need for experimental training data to design novel molecules. The company is advancing a pipeline focused on oncology and other areas of high unmet medical need. By leveraging a physics-first approach, AQEMIA aims to accelerate hit identification and lead optimization, potentially reducing the time and cost of bringing new therapies to patients. The company's innovative methodology positions it at the intersection of AI and computational chemistry, with the potential to disrupt traditional drug discovery paradigms. However, as a private entity with limited publicly available financial and pipeline data, AQEMIA's progress and valuation remain opaque. Its success hinges on demonstrating platform validation through internal programs or partnerships, securing additional funding to advance its pipeline, and translating computational predictions into clinical successes.

Upcoming Catalysts (preview)

• Q3 2026Series B or C Funding Round Announcement70% success
• H2 2026Pharmaceutical Partnership or Licensing Deal60% success
• H1 2027Initiation of First Clinical Trial for Lead Oncology Program40% success